Document is current

Article History

Received: 20 August 2024

Accepted: 30 October 2024

First Online: 21 November 2024

Declarations

:

: Marta Kołt-Kamińska has served as a subinvestigator in clinical studies for Almirall, AnaptysBio, Bristol Myers Squibb, Celltrion, Galderma, Kiniksa, and Novartis. Irena Walecka has served as an investigator or participated in advisory boards and has received honoraria from AbbVie, Almirall, Boehringer Ingelheim, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Polfa, Sanofi, Sandoz, and UCB Pharma. Jacek C Szepietowski has received consulting fees or honoraria from Galderma, AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pierre-Fabre, Pfizer, Sanofi-Genzyme, Trevi, and UCB; and has served as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Galderma, Incyte, InflaRx, Janssen, Kliniksa, Kymab, Menlo Therapeutics, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Trevi Therapeutics, and UCB Pharma. Jacek C Szepietowski is an Editorial Board member of Dermatology and Therapy and he was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Aleksandra Lesiak has served as an investigator or participated in advisory boards for Abbvie, Almirall, AnaptysBio, Boehringer Ingelheim,Dermira, Galderma, Janssen,, LEO Pharma, Novartis, Pierre Fabre, Pfizer, and has received honoraria from Boehringer Ingelheim, Sanofi, Eli Lilly, LEO Pharma, Novartis, Sandoz, Astra Zeneca, Abbvie, Almirall, Alfasigma, UCB. Joanna Narbutt has served as an investigator or participated in advisory boards for AbbVie, Almirall,, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dermira, Galderma, Inflarx, Janssen, Kymab, LEO Pharma, Novartis, Pierre Fabre, Pfizer, Eli Lilly, Novartis, Sandoz, Samsung, Takeda and UCB; Agnieszka Owczarczyk-Saczonek has served as an investigator or participated in advisory boards and has received honoraria from AbbVie, Allergan, Almirall, Amgen, Boehringer Ingelheim, Celltrion, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Pierre-Fabre, Sanofi, Sandoz, and UCB Pharma. Dorota Krasowska has served as an investigator or participated in advisory boards for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celltrion, Dermira, Eli Lilly, Galderma, Galapagos, Inocyte, LEO Pharma, Novartis, Pfizer, and has received honoraria from Abbvie, Boehringer Ingelheim, Eli Lilly, Novartis, Pfizer. Adam Reich has served as an investigator or participated in advisory boards for AbbVie, Almirall, Alvotech, Amgen, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dermira, Galderma, Inflarx, Janssen, Kiniksa, Kymab, LEO Pharma, Novartis, Pierre Fabre, Pfizer, Trevi Therapeutics, and UCB; and has received honoraria from Boehringer Ingelheim, Chema Rzeszow, Eli Lilly, LEO Pharma, Novartis, Sandoz, and Takeda. Adam Reich is an Editorial Board member of Dermatology and Therapy and he was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Luiza Marek-Józefowicz, Piotr Krajewski, Julia Nowowiejska, Aleksandra Siekierko, Ewa Duchnik, Katarzyna Jóźwicka, Magdalena Kiedrowicz, Mateusz Mleczko, Hubert Arasiewicz, Monika Kucharczyk, Witold Owczarek, Iwona Flisiak, Mariola Marchlewicz, and Beata Kręcisz declare no conflict of interest.

: The study was conducted in accordance with the principles of the Declaration of Helsinki and the ethical and institutional regulations of each participating center. Due to retrospective nature of the study, according to Polish law ethical approval was not required. Upon collection, all data were anonymized prior to any further analysis.

: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.